First human tests for new chikungunya shot
NCT ID NCT06669208
Summary
This early-stage trial tested a new vaccine designed to protect against chikungunya virus infection. It involved 48 healthy adults to check if the vaccine was safe and if it successfully triggered an immune response. Participants received two shots of either the vaccine or a placebo, and researchers monitored them for side effects and signs of immunity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA FEVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States
Conditions
Explore the condition pages connected to this study.